Stoke Therapeutics, Inc.

NASDAQ:STOK

Biotechnology

Healthcare
$26.69 -1.12%

-$0.34 today

Market cap
$1.75B
Beta
1.19
P/E (TTM)
-11.1
EPS (TTM)
-$2.69
52W Low $11.17High $40.22

Volume 0.76M

Average 0.64M

STOK EPS (Diluted)

Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.

Stoke Therapeutics, Inc.NASDAQ: STOK

EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026

EPS (Diluted) turns negative

Q1 FY2026 EPS (Diluted) was -$0.79, compared with $1.9 a year earlier. Trailing-twelve-month EPS (Diluted) was -$2.83.

Context

  • EPS (Diluted) grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Diluted) reaches the consensus estimate from 9 analysts of -$3.96 (-3201.7%) for the fiscal year ending Dec 2026, a slowdown from the +92.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.79+20.2% QoQ
Last fiscal yearDec 2025
-$0.12+92.7% YoY
LTMMar 2026
-$2.83-458.2% YoY
EPS (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-141.6%-98.8%+42.8 pp
1 year+92.7%-3201.7%-3294.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Diluted) history

USD · from the income statement

Latest · FY2025
(0.12) USD
Year-over-year change
+92.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Diluted) vs competitors

How STOK compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -458.2% is the lowest of 6, against a peer median of -26.2%.
STOK Competitors
EPS (Diluted) for STOK and competitors
Company Period LTM YoY 3-year CAGR
PRQRProQR Therapeutics N.V.LTM Mar 2026-€0.44 EUR-27.1%—
BEAMBeam Therapeutics Inc.LTM Jun 2026-$0.86 USD+80.9%—
WVEWave Life Sciences Ltd.LTM Mar 2026-$1.06 USD-26.2%—
DSGNDesign Therapeutics, Inc.LTM Mar 2026-$1.2 USD-21.2%—
STOKStoke Therapeutics, Inc.LTM Mar 2026-$2.83 USD-458.2%—
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$3.32 USD-94.2%—
SLNSilence Therapeutics plcLTM Mar 2026-$4.32 USD——
Peer median (excluding STOK) —-26.2%—

Competitors are the stored peer set for STOK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue012.41M8.78M36.56M184.42M
Cost of Revenue00000
Gross Profit012.41M8.78M36.56M184.42M
Gross Margin—100.0%100.0%100.0%100.0%
Research & Development54.17M77.84M82.23M89.13M137.92M
Selling, General & Admin31.9M38.92M41.32M48.79M67.09M
Operating Expenses86.07M116.76M123.55M137.93M205.01M
Depreciation & Amortization974K1.55M2.47M2.18M1.77M
EBITDA(84.83M)(99.52M)(102.23M)(86.8M)(5.12M)
EBITDA Margin—-802.3%-1164.4%-237.5%-2.8%
Operating Income(86.07M)(104.36M)(114.77M)(101.37M)(20.59M)
Operating Margin—-841.2%-1307.2%-277.3%-11.2%
Interest Income120K3.12M9.91M12.64M13.77M
Interest Expense00009K
Other Income / Expenses260K3.29M10.07M12.39M13.71M
Income Before Tax(85.81M)(101.07M)(104.7M)(88.98M)(6.89M)
Pre-Tax Margin—-814.7%-1192.5%-243.4%-3.7%
Income Tax Expense00000
Net Income(85.81M)(101.07M)(104.7M)(88.98M)(6.89M)
Net Margin—-814.7%-1192.5%-243.4%-3.7%
EPS (Basic)(2.34)(2.60)(2.38)(1.65)(0.12)
EPS (Diluted)(2.34)(2.60)(2.38)(1.65)(0.12)
Weighted Avg Shares36.74M38.9M43.99M54.01M59.22M
Weighted Avg Shares (Diluted)36.74M38.9M43.99M54.01M59.22M

Stoke Therapeutics, Inc.

NASDAQ:STOK

Intrinsic Alpha fair value

Locked

Current Price

$26.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.